{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:26:17Z","timestamp":1792131977118,"version":"4.4.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Responders to melphalan therapy are characterized by slower rates of NER and DSB\/R mechanisms and higher apoptotic rates. The DSB\/R inhibitor SCR7 enhances cytotoxicity of melphalan against myeloma plasma cells.<\/jats:p>","DOI":"10.1182\/blood-2016-01-691618","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T02:43:40Z","timestamp":1469155420000},"page":"1214-1225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7"],"prefix":"10.1182","volume":"128","author":[{"given":"Maria","family":"Gkotzamanidou","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"},{"name":"Department of Clinical Therapeutics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bamia","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilis L.","family":"Souliotis","sequence":"additional","affiliation":[{"name":"Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111905033725100_B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma.","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111905033725100_B2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma.","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"2019111905033725100_B3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nrclinonc.2010.104","article-title":"200 mg\/m2 melphalan--the gold standard for multiple myeloma.","volume":"7","author":"Giralt","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"2019111905033725100_B4","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111905033725100_B5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111905033725100_B6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jphp.12072","article-title":"Carfilzomib: a novel agent for multiple myeloma.","volume":"65","author":"Redic","year":"2013","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"2019111905033725100_B7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","article-title":"The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.","volume":"30","author":"Anderson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111905033725100_B8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111905033725100_B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11864-014-0276-6","article-title":"New approaches to management of multiple myeloma.","volume":"15","author":"Genadieva-Stavric","year":"2014","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"2019111905033725100_B10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jms.1009","article-title":"Quantitative determination of melphalan DNA adducts using HPLC - inductively coupled mass spectrometry.","volume":"41","author":"Edler","year":"2006","journal-title":"J Mass Spectrom"},{"issue":"4","key":"2019111905033725100_B11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0921-8777(01)00092-1","article-title":"Repair of DNA interstrand cross-links.","volume":"486","author":"Dronkert","year":"2001","journal-title":"Mutat Res"},{"issue":"10","key":"2019111905033725100_B12","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1158\/0008-5472.CAN-08-3489","article-title":"Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.","volume":"69","author":"Episkopou","year":"2009","journal-title":"Cancer Res"},{"issue":"1-2","key":"2019111905033725100_B13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mrfmmm.2009.02.003","article-title":"Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.","volume":"668","author":"Thompson","year":"2009","journal-title":"Mutat Res"},{"issue":"7","key":"2019111905033725100_B14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer.","volume":"11","author":"Deans","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"3-4","key":"2019111905033725100_B15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000138882","article-title":"Loss of homologous recombination or non-homologous end-joining leads to radial formation following DNA interstrand crosslink damage.","volume":"121","author":"Hanlon Newell","year":"2008","journal-title":"Cytogenet Genome Res"},{"issue":"12","key":"2019111905033725100_B16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy.","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"2019111905033725100_B17","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1093\/nar\/gki749","article-title":"Base excision repair intermediates are mutagenic in mammalian cells.","volume":"33","author":"Simonelli","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2019111905033725100_B18","doi-asserted-by":"crossref","first-page":"e69061","DOI":"10.1371\/journal.pone.0069061","article-title":"The efficiency of homologous recombination and non-homologous end joining systems in repairing double-strand breaks during cell cycle progression.","volume":"8","author":"Bee","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019111905033725100_B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4161\/cbt.13.2.18872","article-title":"Inhibiting homologous recombination for cancer therapy.","volume":"13","author":"Chernikova","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2019111905033725100_B20","first-page":"305","article-title":"Gamma-H2AX - a novel biomarker for DNA double-strand breaks.","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo"},{"issue":"1","key":"2019111905033725100_B21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bcp.2008.03.025","article-title":"Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.","volume":"76","author":"Clingen","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2019111905033725100_B22","doi-asserted-by":"crossref","first-page":"e0117654","DOI":"10.1371\/journal.pone.0117654","article-title":"Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.","volume":"10","author":"Stefanou","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"2019111905033725100_B23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0961203314565413","article-title":"Increased DNA double-strand breaks and enhanced apoptosis in patients with lupus nephritis.","volume":"24","author":"Souliotis","year":"2015","journal-title":"Lupus"},{"issue":"18","key":"2019111905033725100_B24","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-10-0984","article-title":"Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.","volume":"16","author":"Plummer","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7381","key":"2019111905033725100_B25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy.","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"2019111905033725100_B26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"issue":"19","key":"2019111905033725100_B27","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1182\/blood-2011-02-339432","article-title":"Cytokinetically quiescent (G0\/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1\/2.","volume":"118","author":"Pei","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111905033725100_B28","doi-asserted-by":"crossref","first-page":"e55493","DOI":"10.1371\/journal.pone.0055493","article-title":"An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.","volume":"8","author":"Sousa","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"2019111905033725100_B29","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1182\/blood-2004-07-2888","article-title":"Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.","volume":"105","author":"Deriano","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111905033725100_B30","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood-2003-07-2527","article-title":"A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.","volume":"103","author":"Willmore","year":"2004","journal-title":"Blood"},{"issue":"15","key":"2019111905033725100_B31","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111905033725100_B32","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma.","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111905033725100_B33","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1365-2125.2012.04274.x","article-title":"Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.","volume":"74","author":"Stefanou","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2019111905033725100_B34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.dnarep.2006.05.006","article-title":"Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.","volume":"5","author":"Souliotis","year":"2006","journal-title":"DNA Repair (Amst)"},{"issue":"1-2","key":"2019111905033725100_B35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.mrfmmm.2011.06.012","article-title":"The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect.","volume":"714","author":"Episkopou","year":"2011","journal-title":"Mutat Res"},{"issue":"5","key":"2019111905033725100_B36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/leu.2013.284","article-title":"Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.","volume":"28","author":"Gkotzamanidou","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"2019111905033725100_B37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00280-002-0507-6","article-title":"In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.","volume":"50","author":"Avramis","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2019111905033725100_B38","first-page":"995","article-title":"Development and characterization of a melphalan-resistant human multiple myeloma cell line.","volume":"51","author":"Bellamy","year":"1991","journal-title":"Cancer Res"},{"issue":"11","key":"2019111905033725100_B39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1593\/neo.111032","article-title":"DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.","volume":"13","author":"Stronach","year":"2011","journal-title":"Neoplasia"},{"issue":"3","key":"2019111905033725100_B40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1124\/jpet.106.118356","article-title":"Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.","volume":"321","author":"Amrein","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"2019111905033725100_B41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.cell.2012.11.054","article-title":"An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression.","volume":"151","author":"Srivastava","year":"2012","journal-title":"Cell"},{"issue":"15","key":"2019111905033725100_B42","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1093\/nar\/gks353","article-title":"RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.","volume":"40","author":"Budke","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2019111905033725100_B43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/bjc.2014.410","article-title":"Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.","volume":"111","author":"Gkotzamanidou","year":"2014","journal-title":"Br J Cancer"},{"issue":"12","key":"2019111905033725100_B44","first-page":"4465","article-title":"Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.","volume":"9","author":"Souliotis","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111905033725100_B45","doi-asserted-by":"crossref","first-page":"e39588","DOI":"10.1371\/journal.pone.0039588","article-title":"Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response.","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"2019111905033725100_B46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.V100.1.224","article-title":"Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.","volume":"100","author":"Spanswick","year":"2002","journal-title":"Blood"},{"issue":"19","key":"2019111905033725100_B47","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2005.07.385","article-title":"Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111905033725100_B48","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3324\/haematol.11435","article-title":"Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.","volume":"92","author":"Dimopoulos","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"2019111905033725100_B49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.dnarep.2005.04.007","article-title":"Nucleotide excision repair in chromatin and the right of entry.","volume":"4","author":"Gong","year":"2005","journal-title":"DNA Repair (Amst)"},{"issue":"7","key":"2019111905033725100_B50","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.dnarep.2007.02.003","article-title":"Translesion synthesis: Y-family polymerases and the polymerase switch.","volume":"6","author":"Lehmann","year":"2007","journal-title":"DNA Repair (Amst)"},{"issue":"20","key":"2019111905033725100_B51","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1038\/sj.emboj.7601344","article-title":"The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks.","volume":"25","author":"Hanada","year":"2006","journal-title":"EMBO J"},{"issue":"1","key":"2019111905033725100_B52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2008.08.015","article-title":"Mre11 nuclease activity has essential roles in DNA repair and genomic stability distinct from ATM activation.","volume":"135","author":"Buis","year":"2008","journal-title":"Cell"},{"issue":"7","key":"2019111905033725100_B53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dnarep.2007.02.006","article-title":"DNA double-strand break repair: from mechanistic understanding to cancer treatment.","volume":"6","author":"Helleday","year":"2007","journal-title":"DNA Repair (Amst)"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/9\/1214\/1399286\/1214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/9\/1214\/1399286\/1214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T10:04:03Z","timestamp":1574157843000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/9\/1214\/35794\/DNA-repair-of-myeloma-plasma-cells-correlates-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-691618","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}